Compass pathways stock forecast.

We are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. News & events. News releases. SEC filings & annual reports. Our annual review. Stock information. Stock quote & chart. Historical price lookup. Corporate governance.Web

Compass pathways stock forecast. Things To Know About Compass pathways stock forecast.

Nikkei 225. 30,696.96. -0.95%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Compass Pathways PLC (CMPS.OQ) real-time stock quotes, news, price and financial information from ...A high-level overview of COMPASS Pathways plc (CMPS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Dec 26, 2020 · Despite having an IPO just three months ago, Compass Pathways ( CMPS -3.64%) is already up a staggering 224% from its IPO price of $17. If you invested $10,000 in its first-ever public offering ... 2 de set. de 2022 ... ... stock could be Wall Street's biggest winner of the 2020s. Listen to the Podcast ➡️Spotify: https://open.spotify.com/show ...

In the last 3 months, 5 analysts have offered 12-month price targets for Compass Pathways. The company has an average price target of $50.6 with a high of $120.00 and a low of $19.00. Below is a ...A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. As at September 2021, COMPASS Pathways had cash of US$294m and no debt ...WebNov 13, 2021 · A buy now? Luckily, Compass Pathways stock doesn't have a rousing success for COMP360 already baked into its price. The company's market cap of $1.4 billion at the moment isn't terribly high for a ...

Learn More. Market Cap. (-2.86%) -$0.17. Current Price. The biotech is developing a treatment paradigm combining talk therapy with a purified version of psilocybin, the active ingredient in "magic ...Nov 29, 2023 · About CMPS. COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.

How to buy COMPASS Pathways PLC stock on Stash. 1. Enter the amount you'd like to invest in COMPASS Pathways PLC stock, then proceed to checkout. Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a ...It is one of the best psychedelic stocks to invest in. On December 15, EF Hutton analyst Elemer Piros initiated coverage of COMPASS Pathways plc (NASDAQ:CMPS) with a Buy rating and a $38 price target.Compass Pathways Plc stock forecasts for 2023-2027. Date: Open Price: Close Price: Change: Compass Pathways Plc Stock Forecast for 2023: January 2023: 2.04: 1.02-50% ...COMPASS Pathways has a market cap of $299.3 million, and a 52-week range of $6.74 to $49.52. The stock has a price/book ratio of 1.32, and a price-to-free-cash-flow ratio of -6.9.Web

Nov 13, 2023 · Future criteria checks 0/6. COMPASS Pathways's earnings are forecast to decline at 2.7% per annum while its annual revenue is expected to grow at 82.4% per year. EPS is expected to grow by 6.1% per annum. Return on equity is forecast to be -82.5% in 3 years.

Stock Price Forecast. The 5 analysts offering 12-month price forecasts for Compass Pathways PLC have a median target of 38.00, with a high estimate of 120.00 and a low estimate of 22.00. The median estimate represents a +488.24% increase from the last price of 6.46.

*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart. COMPASS Pathways Analyst Opinions. All. All ...COMPASS Pathways - Overview (February Company Presentation) Recent Events: Compass posted fourth quarter results one week ago. The company posted a net loss of $25.7 million for the quarter and ...Compass Pathways (CMPS) buy sell technical analysis & forecast predictions with share price targets for today short term. Compass Pathways (CMPS) Share trades in NASDAQ in NASDAQ stock exchange. Important intraday levels for the stock on upside are: 18 and 19 and 21 If the stock moves up, then it will find resistance near these levels.Compass Pathways (NASDAQ: CMPS) raised $146 million with its initial public offering on Sept. 18. While the IPO's price was set at $17, on the first day of trading, it opened at $23.40 and closed ...Next reporting date. March 27, 2024. EPS forecast (this quarter) -$0.22. Annual revenue (last year) $233.0K. Annual profit (last year) -$152.4M.Stock Price Forecast. The 5 analysts offering 12-month price forecasts for Compass Pathways PLC have a median target of 38.00, with a high estimate of 120.00 and a low estimate of 22.00. The median estimate represents a +488.24% increase from the last price of 6.46.

Stock analysis for Compass Pathways Plc (CMPS:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.The latest price target for Compass Pathways ( NASDAQ: CMPS) was reported by Cantor Fitzgerald on Tuesday, August 22, 2023. The analyst firm set a price target for 21.00 expecting CMPS to rise to ...WebWhile Compass Pathways' (CMPS 0.84%) stock is near $8, the analysts on Wall Street are figuring, on average, that its shares will explode by 458% to reach around $42.30 within the next 12 months.On another note, COMPASS Pathways has 4 warning signs (and 2 which make us uncomfortable) we think you should know about. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies insiders are buying, and this list of stocks growth stocks (according to analyst forecasts)Aug 16, 2023 · Psychedelics biotech giant COMPASS Pathways (NASDAQ: CMPS) has entered into a securities purchase agreement for an initial $125 million and potential additional of $160 million, with a select ...

Nov 27, 2023 · The Compass Pathways PLC stock price fell by -6.05% on the last day (Monday, 27th Nov 2023) from $6.45 to $6.06. During the last trading day the stock fluctuated 13.20% from a day low at $5.80 to a day high of $6.56. The price has risen in 6 of the last 10 days and is up by 14.99% over the past 2 weeks. Volume has increased on the last day by ...

The current Compass Pathways PLC [ CMPS] share price is $6.10. The Score for CMPS is 44, which is 12% below its historic median score of 50, and infers higher risk than normal. CMPS is currently trading in the 40-50% percentile range relative to its historical Stock Score levels. Compass Pathways Plc. Market Cap. $399M. Today's Change. (6.61%) $0.40. Current Price. $6.45. Price as of November 24, 2023, 1:00 p.m. ET. You’re reading a free article with opinions that may ...Last Friday, U.K.-based Compass Pathways (NASDAQ: CMPS) became the first psychedelic medicine company to go public on a major U.S. exchange. The drugmaker's shares promptly rose by an eye-catching ...Next reporting date. March 27, 2024. EPS forecast (this quarter) -$0.22. Annual revenue (last year) $233.0K. Annual profit (last year) -$152.4M.Dec 1, 2023 · COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. One reason why now's a decent time to buy psychedelics stocks is that there's an ongoing fire sale across the entire industry, thanks to the bear market. Leaders like COMPASS Pathways ( CMPS 3.22% ...Last Friday, U.K.-based Compass Pathways (NASDAQ: CMPS) became the first psychedelic medicine company to go public on a major U.S. exchange. The drugmaker's shares promptly rose by an eye-catching ...The upgrade of COMPASS Pathways PLC Sponsored ADR to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move ...

For COMPASS Pathways plc stock forecast for 2023, 2 predictions are offered for each month of 2023 with average COMPASS Pathways plc stock forecast of $5.33, a high forecast of $5.36, and a low forecast of $5.3. The average COMPASS Pathways plc stock forecast 2023 represents a 0.88% increase from the last price of $5.28499984741211.

AnaptysBio presently has a consensus target price of $29.00, suggesting a potential upside of 105.09%. COMPASS Pathways has a consensus target price of $46.83, suggesting a potential upside of 683.17%. Given AnaptysBio's stronger consensus rating and higher probable upside, analysts plainly believe COMPASS Pathways is more …

LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...How to buy COMPASS Pathways PLC stock on Stash. 1. Enter the amount you'd like to invest in COMPASS Pathways PLC stock, then proceed to checkout. Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.About the COMPASS Pathways Plc stock forecast. As of 2023 November 27, Monday current price of CMPS stock is 6.450$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).Future criteria checks 0/6. COMPASS Pathways's earnings are forecast to decline at 2.7% per annum while its annual revenue is expected to grow at 82.4% per year. EPS is expected to grow by 6.1% per annum. Return on equity is forecast to be -82.5% in 3 years.Market Activity. Funds + ETFs. Analyst ratings can be used in addition to other personal research work prior to making investment decisions. Do Not Sell My Personal Information (CA Residents Only ... Shares of Compass Pathways PLC pointed north out of the gate, as the first trade was 37.6% above the initial public offering price. The said Friday that it's upsized , above the …On average, Wall Street analysts predict that Compass Pathways 's share price could reach $57.25 by Aug 22, 2024. The average Compass Pathways stock price prediction …Get Compass Pathways PLC (CMPS.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments.The Compass Pathways Plc (CMPS) stock price forecast for the next 12 months is generally positive, with an average analyst price target of $20.62, representing a +291.30% increase from the current price of $5.27. The highest analyst price target is $35.17, and the lowest is $6.0744.Compass Pathways. Compass Pathways’ roots go back to 2015, when George Goldsmith and Ekaterina Malievskaia founded a nonprofit organization, the Compass Trust Limited, to support research and ...Jul 6, 2023 · The 10 analysts offering 12-month price forecasts for Compass Pathways PLC have a median target of 33.00, with a high estimate of 120.00 and a low estimate of 19.00. This indicates a potential increase of 254.08% from the last recorded price of 9.32. The consensus among 11 polled investment analysts is to buy stock in Compass Pathways PLC. COMP360 Overview (August Company Presentation) Psilocybin is a hallucinogenic chemical found in psychedelic mushrooms. It also is in Phase II clinical trials for the treatment of post-traumatic ...Web

16 de ago. de 2023 ... ... Price” requirement (as defined in the Nasdaq rules). COMPASS intends to use the net proceeds from the proposed financing to fund its pivotal ...CMPS : Long term COMPASS Pathways plc stock forecast for 2022, 2023 (1 year) - 2025 - 2027 (5 year) - 2030, and 2032 (10 year). Forecast for 2024 Jan. is $6.19 ...Feb 7, 2023 · 3. Compass Pathways. Compass Pathways (CMPS 6.61%) isn't a large holding for Wood. The psychedelic stock makes up less than 1% of her Ark Genomic Revolution ETF's portfolio. However, Compass ... Beam Therapeutics (BEAM-1.72%), COMPASS Pathways (CMPS-6.05%), ... The average price target for the stock is $41.67, implying a 382% upside potential from its current share price. Like Beam ...Instagram:https://instagram. pro dashboardvanguard vbiaxbest dividend stocks under dollar10swing trade ideas And the biotechnology industry's average price-to-sales multiple is 4.7. Thus, if Compass manages to capture a mere 10% of that per year, it could be bringing in $139 million in revenue. Assuming ...WebStock Price Forecast. The 5 analysts offering 12-month price forecasts for Compass Pathways PLC have a median target of 38.00, with a high estimate of 120.00 and a low estimate of 22.00. The median estimate represents a +488.24% increase from the last price of 6.46. aarp dental savings plansmsft ex dividend date The financials. The average price target from the nine analysts following COMPASS pathways is $68 against a current price of $14.9, implying a 356% upside and a target market cap of $3 billion. I ...These psychedelic sector stocks are generating a buzz among investors. ... Compass Pathways PLC -26.3%: Incannex Healthcare Ltd. -69.6% ... Commercial Real Estate Outlook for 2024. good sectors to invest in COMPASS Pathways (CMPS) Fundamentals Checker. Financial metrics are used to evaluate financial stability which helps analysts determine if COMPASS Pathways is undervalued compared to its fair value. A company's financial health can strongly influence the stock forecast.Can Compass Pathways' Stock Gain 458% Like Wall Street Is Expecting? Wall Street might have the timing wrong, but their hopes aren't misplaced. Alex Carchidi | Jul 1, 2023Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression, and launches new research center. Read more. Compass is a biotechnology company dedicated to accelerating patient access and experience to evidence-based innovation in mental health care.